FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2425385554> ?p ?o ?g. }

• W2425385554 endingPage "7521" @default.
• W2425385554 startingPage "7521" @default.
• W2425385554 abstract "7521^ Background: NSCLC patients whose tumors harbor epidermal growth factor receptor EGFR/HER1 mutations represent a unique subpopulation with unparalleled responsiveness to EGFR tyrosine kinase inhibitors. A phase II study of BIBW 2992 – an oral, novel, potent irreversible inhibitor of EGFR and human HER2 – has completed accrual in Taiwan and the US. Methods: Patients with a stage IIIB/IV lung adenocarcinoma, EGFR mutations in exons 18–21 (by direct sequencing), chemo-naïve or with progressive disease following first-line cytotoxic chemotherapy, measurable disease, and ECOG PS 0–2 received 50 mg or 40 mg BIBW 2992 qd until progression. Response was assessed at 4, 8 and 12 weeks, and at 8-weekly intervals thereafter; images were centrally reviewed. Analysis included primary endpoint objective response rate (ORR) and secondary endpoint progression-free survival (PFS). Results: 444 patients were tested for EGFR mutations and 129 received treatment. Tumor size reduction was seen in 90% of patients. ORR and disease control rate (DCR) was 62% and 94%, respectively, for del19; 52% and 85% for L858R; and 43% and 78% for other mutations based on investigator assessment. L858R mutation was seen in 54 (42%), del19 in 52 (40%) and other mutations in 23 (18%) patients. Median PFS was estimated to be 12 months (95% CI: 10–19.2) for the overall group, 12 months (95% CI: 10–19.2) in del19, 16.3 months (95% CI:10–Inf) in L858R, and 15.6 months (95% CI:10–19.2) when combined. The most common drug-related adverse events (AEs) were diarrhea and rash/acne, as reported in 95% of patients each and were Grade 3 in 18% and 19% of patients, respectively. No Grade 4 cases were reported for these events. Conclusions: Administration of BIBW 2992 resulted in a high ORR, DCR and PFS in NSCLC patients with EGFR mutations. Gastrointestinal and skin disorders were the most frequently observed AEs and were manageable with adequate supportive care and dose reduction. Updated response and PFS data based on independent imaging review will be presented. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Boehringer Ingelheim Boehringer Ingelheim In compliance with the guidelines established by the ASCO Conflict of Interest Policy (J Clin Oncol. 2006 Jan 20;24[3]:519-521) and the Accreditation Council for Continuing Medical Education (ACCME), ASCO strives to promote balance, independence, objectivity, and scientific rigor through disclosure of financial and other interests, and identification and management of potential conflicts. According to the ASCO Conflict of Interest Policy, the following financial and other relationships must be disclosed: employment or leadership position, consultant or advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration (J Clin Oncol. 2006 Jan 20;24[3]:520). The ASCO Conflict of Interest Policy disclosure requirements apply to all authors who submit abstracts to the Annual Meeting. For clinical trials that began accrual on or after April 29, 2004, ASCO's Policy places some restrictions on the financial relationships of principal investigators (J Clin Oncol. 2006 Jan 20;24[3]:521). If a principal investigator holds any restricted relationships, his or her abstract will be ineligible for placement in the 2010 Annual Meeting unless the ASCO Ethics Committee grants an exception. Among the circumstances that might justify an exception are that the principal investigator (1) is a widely acknowledged expert in a particular therapeutic area; (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research. NIH-sponsored trials are exempt from the Policy restrictions. Abstracts for which authors requested and have been granted an exception in accordance with ASCO's Policy are designated with a caret symbol (^) in the Annual Meeting Proceedings. For more information about the ASCO Conflict of Interest Policy and the exceptions process, please visit www.asco.org/conflictofinterest." @default.
• W2425385554 created "2016-06-24" @default.
• W2425385554 creator A5001840595 @default.
• W2425385554 creator A5004559185 @default.
• W2425385554 creator A5018594526 @default.
• W2425385554 creator A5018761671 @default.
• W2425385554 creator A5025150511 @default.
• W2425385554 creator A5038687249 @default.
• W2425385554 creator A5047021501 @default.
• W2425385554 creator A5058369418 @default.
• W2425385554 creator A5072921786 @default.
• W2425385554 creator A5076810872 @default.
• W2425385554 date "2010-05-20" @default.
• W2425385554 modified "2023-09-25" @default.
• W2425385554 title "A phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2)." @default.
• W2425385554 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.7521" @default.
• W2425385554 hasPublicationYear "2010" @default.
• W2425385554 type Work @default.
• W2425385554 sameAs 2425385554 @default.
• W2425385554 citedByCount "25" @default.
• W2425385554 countsByYear W24253855542012 @default.
• W2425385554 countsByYear W24253855542015 @default.
• W2425385554 crossrefType "journal-article" @default.
• W2425385554 hasAuthorship W2425385554A5001840595 @default.
• W2425385554 hasAuthorship W2425385554A5004559185 @default.
• W2425385554 hasAuthorship W2425385554A5018594526 @default.
• W2425385554 hasAuthorship W2425385554A5018761671 @default.
• W2425385554 hasAuthorship W2425385554A5025150511 @default.
• W2425385554 hasAuthorship W2425385554A5038687249 @default.
• W2425385554 hasAuthorship W2425385554A5047021501 @default.
• W2425385554 hasAuthorship W2425385554A5058369418 @default.
• W2425385554 hasAuthorship W2425385554A5072921786 @default.
• W2425385554 hasAuthorship W2425385554A5076810872 @default.
• W2425385554 hasConcept C121608353 @default.
• W2425385554 hasConcept C126322002 @default.
• W2425385554 hasConcept C143998085 @default.
• W2425385554 hasConcept C197934379 @default.
• W2425385554 hasConcept C203092338 @default.
• W2425385554 hasConcept C2776256026 @default.
• W2425385554 hasConcept C2776694085 @default.
• W2425385554 hasConcept C2777930144 @default.
• W2425385554 hasConcept C2778822529 @default.
• W2425385554 hasConcept C2779438470 @default.
• W2425385554 hasConcept C2780580887 @default.
• W2425385554 hasConcept C2781182431 @default.
• W2425385554 hasConcept C31760486 @default.
• W2425385554 hasConcept C535046627 @default.
• W2425385554 hasConcept C71924100 @default.
• W2425385554 hasConcept C90924648 @default.
• W2425385554 hasConceptScore W2425385554C121608353 @default.
• W2425385554 hasConceptScore W2425385554C126322002 @default.
• W2425385554 hasConceptScore W2425385554C143998085 @default.
• W2425385554 hasConceptScore W2425385554C197934379 @default.
• W2425385554 hasConceptScore W2425385554C203092338 @default.
• W2425385554 hasConceptScore W2425385554C2776256026 @default.
• W2425385554 hasConceptScore W2425385554C2776694085 @default.
• W2425385554 hasConceptScore W2425385554C2777930144 @default.
• W2425385554 hasConceptScore W2425385554C2778822529 @default.
• W2425385554 hasConceptScore W2425385554C2779438470 @default.
• W2425385554 hasConceptScore W2425385554C2780580887 @default.
• W2425385554 hasConceptScore W2425385554C2781182431 @default.
• W2425385554 hasConceptScore W2425385554C31760486 @default.
• W2425385554 hasConceptScore W2425385554C535046627 @default.
• W2425385554 hasConceptScore W2425385554C71924100 @default.
• W2425385554 hasConceptScore W2425385554C90924648 @default.
• W2425385554 hasIssue "15_suppl" @default.
• W2425385554 hasLocation W24253855541 @default.
• W2425385554 hasOpenAccess W2425385554 @default.
• W2425385554 hasPrimaryLocation W24253855541 @default.
• W2425385554 hasRelatedWork W1602357875 @default.
• W2425385554 hasRelatedWork W1787021181 @default.
• W2425385554 hasRelatedWork W1964479812 @default.
• W2425385554 hasRelatedWork W2117036891 @default.
• W2425385554 hasRelatedWork W2425385554 @default.
• W2425385554 hasRelatedWork W2518488558 @default.
• W2425385554 hasRelatedWork W2888534976 @default.
• W2425385554 hasRelatedWork W2889523320 @default.
• W2425385554 hasRelatedWork W3171492215 @default.
• W2425385554 hasRelatedWork W2103674109 @default.
• W2425385554 hasVolume "28" @default.
• W2425385554 isParatext "false" @default.
• W2425385554 isRetracted "false" @default.
• W2425385554 magId "2425385554" @default.
• W2425385554 workType "article" @default.